Key Takeaways
- • Bessemer Venture Partners is leading a $110M Series A in Boltz, a London-based AI research lab building foundation models for biomolecular modeling, small-molecule design and protein design.
- • Boltz's open-source models, which emerged from MIT's CSAIL and Jameel Clinic, have more than 5 million downloads and are used by over 100,000 scientists across thousands of biotechs, labs and top-20 pharma companies.
- • Boltz launched BoltzMol-1 in June, which the company says cuts time to a validated hit from months to weeks and cost from hundreds of thousands of dollars to as low as $10,000.
- • BoltzProt-1, also launched by Boltz, is reported to have nearly triple the hit rate of BoltzGen and to produce designs that pass developability criteria.
- • Boltz's platform is deployed at top-20 pharma companies including Pfizer, Takeda, GSK and Bristol Myers Squibb, as well as DSM Firmenich.
Summary
The three co-founders were core developers of the original open-source models. CEO Gabriele Corso won the Best Student Paper Award at the NeurIPS 2022 SBM workshop for DiffDock, an early model that treated molecular docking as a generative problem. CTO Jeremy Wohlwend led Boltz-1 for structure prediction, Head of Research Saro Passaro built Boltz-2 for joint structure and affinity co-folding, and founding scientist Hannes Stärk led development of BoltzGen, which Bessemer describes as one of the most widely used models for generative protein design. Bessemer says every partnership Boltz has established began as inbound interest from computational chemists and biologists.
Since launching in January, Boltz has expanded from open-source models into a commercial platform. In June it launched BoltzMol-1, a small-molecule design model, and BoltzProt-1, a protein design model. Per Bessemer, the platform allows scientists to move from structure prediction to binding prediction to molecular design within a single workflow. The company offers a Boltz API, hosted inference, fine-tuning services and integrations with AI agents including Claude Code, Codex and Gemini. Bessemer states that the tools are deployed at top-20 pharma companies including Pfizer, Takeda, GSK and Bristol Myers Squibb, along with DSM Firmenich.
Bessemer frames Boltz as part of a broader shift in preclinical R&D, arguing that AI tools will move a significant share of screening and design work from the bench to the computer, analogous to how Cursor and Claude Code have become standard in software development. The firm cites its pharma ROI scorecard, which places molecule identification and structure design in a high adoption, high value category. Publisher materials describe Boltz as a public-benefit company, though the Series A valuation and terms were not disclosed in the source material.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.